Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925076 | 0.85 | CHRNA7 (0.37) | CHRNA7MEN1KMT2AL3MBTL1TP53 | |
| SCHEMBL5003247 | 0.85 | HSP90AB1 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL4999439 | 0.85 | ESR1 (0.34) | MEN1KMT2AL3MBTL1HSP90AA1HSP90AB1 | |
| SCHEMBL5003223 | 0.85 | OXTR (0.35) | MEN1KMT2AL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL14029932 | 0.83 | MEN1 (0.47) | MEN1KMT2AL3MBTL1TP53ALDH1A1 | |
| SCHEMBL14925070 | 0.79 | ESR1 (0.33) | MEN1KMT2AL3MBTL1ALDH1A1LMNA | |
| SCHEMBL14029941 | 0.78 | MAPK1 (0.35) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL14029931 | 0.77 | OXTR (0.36) | MEN1KMT2AL3MBTL1ALDH1A1LMNA | |
| SCHEMBL14029938 | 0.77 | L3MBTL1 (0.53) | MEN1KMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL5006532 | 0.76 | TLR8 (0.43) | MEN1KMT2AL3MBTL1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399464-B2 | using a triazole compound; anticancer agent | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | CHRNA7 4858/4885MEN1 4757/4885KMT2A 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.